239 related articles for article (PubMed ID: 19689330)
1. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.
Stone JM
Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330
[TBL] [Abstract][Full Text] [Related]
2. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.
Poels EM; Kegeles LS; Kantrowitz JT; Slifstein M; Javitt DC; Lieberman JA; Abi-Dargham A; Girgis RR
Mol Psychiatry; 2014 Jan; 19(1):20-9. PubMed ID: 24166406
[TBL] [Abstract][Full Text] [Related]
3. A Review of Molecular Imaging of Glutamate Receptors.
Kim JH; Marton J; Ametamey SM; Cumming P
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081223
[TBL] [Abstract][Full Text] [Related]
4. The association between
Beck K; Arumuham A; Brugger S; McCutcheon RA; Veronese M; Santangelo B; McGinnity CJ; Dunn J; Kaar S; Singh N; Pillinger T; Borgan F; Sementa T; Neji R; Jauhar S; Aigbirhio F; Boros I; Turkheimer F; Hammers A; Lythgoe D; Stone J; Howes OD
J Psychopharmacol; 2022 Sep; 36(9):1051-1060. PubMed ID: 36120998
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism.
Duarte JMN; Xin L
Neurochem Res; 2019 Jan; 44(1):102-116. PubMed ID: 29616444
[TBL] [Abstract][Full Text] [Related]
6. Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.
Bustillo JR; Chen H; Jones T; Lemke N; Abbott C; Qualls C; Canive J; Gasparovic C
JAMA Psychiatry; 2014 Mar; 71(3):265-72. PubMed ID: 24402128
[TBL] [Abstract][Full Text] [Related]
7. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
8. Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.
Javitt DC; Carter CS; Krystal JH; Kantrowitz JT; Girgis RR; Kegeles LS; Ragland JD; Maddock RJ; Lesh TA; Tanase C; Corlett PR; Rothman DL; Mason G; Qiu M; Robinson J; Potter WZ; Carlson M; Wall MM; Choo TH; Grinband J; Lieberman JA
JAMA Psychiatry; 2018 Jan; 75(1):11-19. PubMed ID: 29167877
[TBL] [Abstract][Full Text] [Related]
9. Glutamatergic aspects of schizophrenia.
Tamminga C
Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance Spectroscopy at 4T.
Kim SY; Kaufman MJ; Cohen BM; Jensen JE; Coyle JT; Du F; Öngür D
Biol Psychiatry; 2018 Mar; 83(6):484-491. PubMed ID: 29031411
[TBL] [Abstract][Full Text] [Related]
11. The glutamate hypothesis of schizophrenia: neuroimaging and drug development.
Egerton A; Stone JM
Curr Pharm Biotechnol; 2012 Jun; 13(8):1500-12. PubMed ID: 22283750
[TBL] [Abstract][Full Text] [Related]
12. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
13. Using proton magnetic resonance spectroscopic imaging to study glutamatergic alterations in patients with schizophrenia: A systematic review.
Plitman E; Guma E; Lepage M; Near J; Chakravarty MM
Schizophr Res; 2019 Aug; 210():13-20. PubMed ID: 31272905
[TBL] [Abstract][Full Text] [Related]
14. 7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid, Glutamate, and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings.
Thakkar KN; Rösler L; Wijnen JP; Boer VO; Klomp DW; Cahn W; Kahn RS; Neggers SF
Biol Psychiatry; 2017 Mar; 81(6):525-535. PubMed ID: 27316853
[TBL] [Abstract][Full Text] [Related]
15. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.
Poels EM; Kegeles LS; Kantrowitz JT; Javitt DC; Lieberman JA; Abi-Dargham A; Girgis RR
Schizophr Res; 2014 Feb; 152(2-3):325-32. PubMed ID: 24418122
[TBL] [Abstract][Full Text] [Related]
16. Imaging the glutamatergic system in vivo--relevance to schizophrenia.
Bressan RA; Pilowsky LS
Eur J Nucl Med; 2000 Nov; 27(11):1723-31. PubMed ID: 11105831
[TBL] [Abstract][Full Text] [Related]
17. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
18. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.
Salavati B; Rajji TK; Price R; Sun Y; Graff-Guerrero A; Daskalakis ZJ
Schizophr Bull; 2015 Jan; 41(1):44-56. PubMed ID: 25249654
[TBL] [Abstract][Full Text] [Related]
19. The acute effects of NMDA antagonism: from the rodent to the human brain.
Gunduz-Bruce H
Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
[TBL] [Abstract][Full Text] [Related]
20. Glutamate hypothesis in schizophrenia.
Uno Y; Coyle JT
Psychiatry Clin Neurosci; 2019 May; 73(5):204-215. PubMed ID: 30666759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
